machineMD

machineMD's neos™ automates eye movement exams, eliminating time-intensive manual assessments. Misdiagnosis affects 50% of patients, causing significant harm for 26% and unnecessary procedures for 80%. Traditional 50-minute manual evaluations, needing specialized expertise, are now obsolete.

machineMD began commercialising its first medical device, neos™, in the US and Switzerland in March 2024. Currently, neos™ is a Class I device. CE marking as a Class II product will be completed in September 2024, with FDA Class II approval expected in Q1 of 2025.

machineMD expects to sell approximately 30 devices in 2024, generating revenues of $0.5-1m. These initial devices will be placed primarily with KOLs. Scale-up sales are expected to begin in 2025.

Operating within the digital ophthalmic equipment sector, we cater primarily to ophthalmologists, optometrists, and neurologists. Focused initially on the US and Europe, our reach extends to approximately 120,000 potential customers, representing a market size of $1.1B based on our pricing model. The market holds potential for substantial growth through strategic targeting of opticians and general practitioners, incorporating additional reimbursable clinical tests, and expanding geographically, positioning us in a dynamic and expansive market space.

machineMD revolutionizes eye movement examinations with neos™, a fully automated medical device that supersedes the need for time-intensive manual assessments conducted millions of times daily.

Currently, misdiagnosis affects 50% of patients, leading to significant harm for 26% and unnecessary procedures for 80%. Traditional manual evaluations, taking 50 minutes and requiring scarce specialized expertise, are now obsolete.

This innovation enhances operational efficiency and profitability in eye clinics, optometric practices, and, eventually, retail settings, fostering additional revenue streams. As a result, neos™ is expected to become standard of care and to elevate the quality of patient care significantly.

neos™, a synergy of machineMD’s exclusive software and cutting-edge VR consumer technology, enables technical assistants to perform the examination in just 12 minutes, offering objective, quantifiable, and clinically verified data.

In today's standard of care the main competition is the manual examination of eye and pupil movements. There is not other company offering a comprehensive and fully automized assessment of the brain based on eye and pupil movements. However, there are a few competitors offering VR-based solutions that measure some of the tests needed for assessing the brain based on eye and pupil movements such as https://olleyes.com/

MachineMD's neos™ revolutionizes neuro-ophthalmic diagnostics by providing ophthalmologists and optometrists for the first time with an automated solution that performs comprehensive neuro-ophthalmic examinations on par with specialists. Its state-of-the-art technology combines high-frequency infrared eye tracking with an intuitive head-mounted display, tailored for use in diverse clinical settings. neos™ specifically targets quantifiable neuro-ophthalmologic biomarkers, offering diagnostics that are both precise and focused, surpassing the capabilities of general visual test devices. Designed by neuro-ophthalmology experts, neos™ is adept at identifying crucial functional optic biomarkers, enabling swift and accurate evaluations. With advanced VR, AI, and cloud-based integration, neos™ ensures real-time, efficient assessments, empowering general eye care professionals to deliver specialist-level examinations. This innovation positions neos™ as an essential tool for enhancing the quality of eye care.

machineMD plans a turnover of 60M in 5 years with approx. 6000 customers

machineMD offers neos™ featuring a pay-per-exam model aimed at:
- Cost Efficiency: Ensuring neos™ is more economical than traditional tertiary care routines.
- Market Alignment: Tailoring pricing to fit the CAPEX-driven purchasing trends in ophthalmology.
- Accessible Entry Point: Providing a competitive price to attract even occasional exam performers.
- Usage Incentivization: Encouraging frequent use across various patient cases to embed neos™ in daily clinic operations.
- Lifetime Value Maximization: Fostering enduring client relationships through a model that emphasizes long-term value over initial sales.
Our strategy is to make neos™ a cost-effective, versatile, and indispensable tool in ophthalmic care.

27% Marketing and Sales
39% Product development and clinical studies
7% Quality and Regulatory
11% COGS
2% IP
14% Other

Preferred shares

Market: Slow adoption by clinicians
Product: Longer duration for developing a full diagnostic clinical decision support system

machineMD is a finalist of The Eddies 2024 for the track Medtech/Medical Devices

- Winner of Innovation World Cup 2023
- Finalist of The Eddis Global
- Day One - Switzerland’s leading digital health and medtech accelerator

PCT/EP2022/069622
PCT/EP2022/069623
EP23211966
EP23199219
EP23194392
EP24173935